PMID- 25941327
OWN - NLM
STAT- MEDLINE
DCOM- 20150820
LR  - 20150606
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 194
IP  - 12
DP  - 2015 Jun 15
TI  - Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ 
      dendritic cells induces potent antitumoral responses.
PG  - 5895-902
LID - 10.4049/jimmunol.1500564 [doi]
AB  - The development of vaccines inducing efficient CD8(+) T cell responses is the 
      focus of intense research. Dendritic cells (DCs) expressing the XCR1 chemokine 
      receptor, also known as CD103(+) or CD8alpha(+) DCs, excel in the presentation of 
      extracellular Ags to CD8(+) T cells. Because of its high numbers of DCs, 
      including XCR1(+) DCs, the skin dermis is an attractive site for vaccine 
      administration. By creating laser-generated micropores through the epidermis, we 
      targeted a model protein Ag fused to XCL1, the ligand of XCR1, to dermal XCR1(+) 
      DCs and induced Ag-specific CD8(+) and CD4(+) T cell responses. Efficient 
      immunization required the emigration of XCR1(+) dermal DCs to draining lymph 
      nodes and occurred irrespective of TLR signaling. Moreover, a single intradermal 
      immunization protected mice against melanoma tumor growth in prophylactic and 
      therapeutic settings, in the absence of exogenous adjuvant. The mild inflammatory 
      milieu created in the dermis by skin laser microporation itself most likely 
      favored the development of potent T cell responses in the absence of exogenous 
      adjuvants. The existence of functionally equivalent XCR1(+) dermal DCs in humans 
      should permit the translation of laser-assisted intradermal delivery of a 
      tumor-specific vaccine targeting XCR1(+) DCs to human cancer immunotherapy. 
      Moreover, considering that the use of adjuvants in vaccines is often associated 
      with safety issues, the possibility of inducing protective responses against 
      melanoma tumor growth independently of the administration of exogenous adjuvants 
      should facilitate the development of safer vaccines.
CI  - Copyright (c) 2015 by The American Association of Immunologists, Inc.
FAU - Terhorst, Dorothea
AU  - Terhorst D
AD  - Centre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Universite, 13288 
      Marseille Cedex 9, France; INSERM U1104, 13288 Marseille Cedex 9, France; Centre 
      National de la Recherche Scientifique, Unite Mixte de Recherche 7280, 13288 
      Marseille Cedex 9, France; Department of Dermatology, Charite University 
      Medicine, 10117 Berlin, Germany;
FAU - Fossum, Even
AU  - Fossum E
AD  - K.G. Jebsen Centre for Influenza Vaccine Research, University of Oslo, Oslo 0424, 
      Norway;
FAU - Baranska, Anna
AU  - Baranska A
AD  - Centre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Universite, 13288 
      Marseille Cedex 9, France; INSERM U1104, 13288 Marseille Cedex 9, France; Centre 
      National de la Recherche Scientifique, Unite Mixte de Recherche 7280, 13288 
      Marseille Cedex 9, France;
FAU - Tamoutounour, Samira
AU  - Tamoutounour S
AD  - Centre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Universite, 13288 
      Marseille Cedex 9, France; INSERM U1104, 13288 Marseille Cedex 9, France; Centre 
      National de la Recherche Scientifique, Unite Mixte de Recherche 7280, 13288 
      Marseille Cedex 9, France;
FAU - Malosse, Camille
AU  - Malosse C
AD  - Centre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Universite, 13288 
      Marseille Cedex 9, France; INSERM U1104, 13288 Marseille Cedex 9, France; Centre 
      National de la Recherche Scientifique, Unite Mixte de Recherche 7280, 13288 
      Marseille Cedex 9, France;
FAU - Garbani, Mattia
AU  - Garbani M
AD  - Department of Molecular Allergology, Swiss Institute of Allergy and Asthma 
      Research, University of Zurich, Davos 7270, Switzerland;
FAU - Braun, Reinhard
AU  - Braun R
AD  - Pantec Biosolutions, 9491 Ruggell, Liechtenstein; and.
FAU - Lechat, Elmira
AU  - Lechat E
AD  - Pantec Biosolutions, 9491 Ruggell, Liechtenstein; and.
FAU - Crameri, Reto
AU  - Crameri R
AD  - Department of Molecular Allergology, Swiss Institute of Allergy and Asthma 
      Research, University of Zurich, Davos 7270, Switzerland;
FAU - Bogen, Bjarne
AU  - Bogen B
AD  - K.G. Jebsen Centre for Influenza Vaccine Research, University of Oslo, Oslo 0424, 
      Norway; Center for Immune Regulation, Institute of Immunology, University of Oslo 
      and Oslo University Hospital Rikshospitalet, Oslo 0424 Norway.
FAU - Henri, Sandrine
AU  - Henri S
AD  - Centre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Universite, 13288 
      Marseille Cedex 9, France; INSERM U1104, 13288 Marseille Cedex 9, France; Centre 
      National de la Recherche Scientifique, Unite Mixte de Recherche 7280, 13288 
      Marseille Cedex 9, France; bernardm@ciml.univ-mrs.fr henri@ciml.univ-mrs.fr.
FAU - Malissen, Bernard
AU  - Malissen B
AD  - Centre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Universite, 13288 
      Marseille Cedex 9, France; INSERM U1104, 13288 Marseille Cedex 9, France; Centre 
      National de la Recherche Scientifique, Unite Mixte de Recherche 7280, 13288 
      Marseille Cedex 9, France; bernardm@ciml.univ-mrs.fr henri@ciml.univ-mrs.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150504
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Adaptor Proteins, Vesicular Transport)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Chemokines, C)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (Receptors, Chemokine)
RN  - 0 (TICAM-1 protein, mouse)
RN  - 0 (XC chemokine receptor 1, mouse)
RN  - 0 (Xcl1 protein, mouse)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Adaptor Proteins, Vesicular Transport/metabolism
MH  - Animals
MH  - Cancer Vaccines/administration & dosage/*immunology
MH  - Chemokines, C/genetics/metabolism
MH  - Dendritic Cells/*immunology/*metabolism
MH  - Disease Models, Animal
MH  - Injections, Intradermal
MH  - Melanoma, Experimental
MH  - Mice
MH  - Mice, Knockout
MH  - Myeloid Differentiation Factor 88/metabolism
MH  - Neoplasms/*immunology/pathology/therapy
MH  - Ovalbumin/genetics/immunology
MH  - Protein Binding
MH  - Receptors, Chemokine/genetics/*metabolism
MH  - T-Lymphocyte Subsets/immunology
MH  - Tumor Burden/immunology
EDAT- 2015/05/06 06:00
MHDA- 2015/08/21 06:00
CRDT- 2015/05/06 06:00
PHST- 2015/03/10 00:00 [received]
PHST- 2015/04/15 00:00 [accepted]
PHST- 2015/05/06 06:00 [entrez]
PHST- 2015/05/06 06:00 [pubmed]
PHST- 2015/08/21 06:00 [medline]
AID - jimmunol.1500564 [pii]
AID - 10.4049/jimmunol.1500564 [doi]
PST - ppublish
SO  - J Immunol. 2015 Jun 15;194(12):5895-902. doi: 10.4049/jimmunol.1500564. Epub 2015 
      May 4.